Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
Biohaven reported positive clinical data for Opakalim in epilepsy, highlighting a 3-fold prolongation in time to second seizure in idiopathic generalized epilepsy (IGE) vs. placebo (141 days vs. 47 days). In focal epilepsy, 54% of patients in the open-label extension achieved a ≥50% reduction in seizure frequency, matching competitor efficacy but with significantly lower rates of CNS side effects like dizziness and somnolence.
Key figures
- Drug Name
- Opakalim (BHV-7000)
- Phase Of Trial
- Phase 2/3
- Total subjects studied
- 1000+
- Focal epilepsy ole cohort size
- >100
- Ige seizure prolongation factor
- 3-fold
- Kcnq2 dee seizure reduction pct
- 50%
- Focal epilepsy ole responder rate pct
- 54%
- Ige subjects completed seizure free pct
- 20%
- Ige median time to second seizure placebo days
- 47
- Ige median time to second seizure opakalim days
- 141
- Ige subjects completed without second seizure pct
- 33%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.